Efficacy and Safety Study of DHA-O in Adults With Hypertriglyceridemia
DHA-O
1 other identifier
interventional
93
1 country
1
Brief Summary
The purpose of this study is to investigate the efficacy and safety of DHA-O to lower elevated triglyceride levels in healthy adults with hypertriglyceridemia.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Nov 2012
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2012
CompletedFirst Submitted
Initial submission to the registry
November 27, 2012
CompletedFirst Posted
Study publicly available on registry
November 29, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2013
CompletedApril 25, 2014
April 1, 2014
1 year
November 27, 2012
April 24, 2014
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change from baseline in TG levels
week 14
Secondary Outcomes (1)
Change from baseline in lipid panel measures
week 14
Study Arms (3)
DHA-O
EXPERIMENTALFish oil
ACTIVE COMPARATORPlacebo
PLACEBO COMPARATORInterventions
Eligibility Criteria
You may qualify if:
- ages 18-79
- fasting TG levels, 150-499 mg/dL
- baseline DHA intake \<200mg/d
- active and in good health
You may not qualify if:
- recent diagnosis of CHD or history of revascularization within 6mos of study
- use of lipid altering medications (other than stable statins)
- use of anticoagulants
- use of omega-3 products within 4 weeks of screening
- serum AST/ALT \>1.5x ULN and/or creatinine \>1.5 mg/dL at screening
- lipid altering foods or supplements
- women who are pregnant or of childbearing potential not using adequate birth control
- current use or history of drug or alcohol abuse
- inability to swallow capsules
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Biofortis Clinical Research
Addison, Illinois, 60101, United States
Related Publications (1)
Maki KC, Yurko-Mauro K, Dicklin MR, Schild AL, Geohas JG. A new, microalgal DHA- and EPA-containing oil lowers triacylglycerols in adults with mild-to-moderate hypertriglyceridemia. Prostaglandins Leukot Essent Fatty Acids. 2014 Oct;91(4):141-8. doi: 10.1016/j.plefa.2014.07.012. Epub 2014 Jul 22.
PMID: 25123060DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Kevin Maki, PhD
Biofortis Clinical Research, Inc.
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 27, 2012
First Posted
November 29, 2012
Study Start
November 1, 2012
Primary Completion
November 1, 2013
Study Completion
November 1, 2013
Last Updated
April 25, 2014
Record last verified: 2014-04